Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Clinical trial NCT07621718 · RECRUITING

Trial details

NCT number: NCT07621718
Sponsor: Revolution Medicines, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer Pancreatic Cancer Metastatic PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma Pancreatic Adenosquamous Carcinoma

Start date: 2026-05-22
Primary completion: 2028-12-30
Enrollment: 670

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.